Literature DB >> 19710212

Sonographic follow-up of the access site after arterial angiography: Impact on the detected complication rate.

Alexandra Meis1, Nani Osada, Philip M Schlegel, Roman Fischbach, Walter Heindel, Stephan P Kloska.   

Abstract

OBJECTIVE: This study prospectively evaluated the impact of sonographic follow-up on the detection rate of access site complications in arterial angiography and determined parameters associated with major complications of the access site after arterial angiography.
METHODS: Sonographic follow-up (mean +/- SD, 1.46 +/- 1.11 days after) of the access site (transfemoral, n = 896; and transbrachial, n = 44) was obtained prospectively in 940 arterial angiographies and included evaluations for hematoma, pseudoaneurysm, arteriovenous fistula, arterial dissection, and venous/arterial thrombosis. Clotting parameters, anticoagulation therapy, and several patient and procedure characteristics were recorded. Univariate and multivariate logistic regression analyses were performed.
RESULTS: Sonography depicted major access site complications in 39 of 940 angiographies (4.2%). Major access site complications (major local hematoma, n = 13; retroperitoneal hematoma, n = 1; pseudoaneurysm, n = 18; arterial dissection, n = 1; arteriovenous fistula, n = 1; arterial thrombosis, n = 2; and venous thrombosis, n = 3) required conservative (n = 32 [3.4%]) or surgical (n = 7 [0.7%]) treatment. Independent factors significantly associated with major access site complications were age older than 60.33 years and sheath size greater than 5F (P < .05).
CONCLUSIONS: Major access site complications were detected in 4.2% of cases and were significantly associated with age and sheath size.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710212     DOI: 10.7863/jum.2009.28.9.1151

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  1 in total

Review 1.  [The patient with pulmonary embolism or vascular emergency requiring intensive care].

Authors:  S M Schellong
Journal:  Internist (Berl)       Date:  2010-08       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.